Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title:

A Phase 2a, Randomized, Placebo-Controlled, Double Blind Multiple Ascending Dose Study in Patients With Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06429176
• Other study ID #: SPL84-002
• Secondary ID: 2024-511184-28
• Status: Recruiting
• Phase: Phase 2
• Start date: July 1, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: SpliSense Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation. The purpose of this research study is to: - test the safety and effectiveness of multiple doses of the study drug, SPL84 - test how multiple doses of the drug are processed by the body Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF. Participants will: Take drug SPL84 or a placebo by inhalation every week for 9 weeks months Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2025
• Est. primary completion date: October 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of CF and two CF causing mutations; 3849+10 Kb C->T mutation on one allele in the CF transmembrane conductance regulator (CFTR) gene (homozygote or compound heterozygote). Source documentation from a certified genetic laboratory is required.
• Body mass index (BMI) of = 17 kg/m2.
• FEV1 40-90% predicted at screening.
• Non-smokers or vapers for at least 180 days (6 months) prior to screening, per participant report.

Exclusion Criteria:

• Use of Kalydeco, Orkambi, Symdeko/Symkevi or Trikafta/Kaftrio within 30 days of first dose with study intervention.
• Use of any investigational drug (other than SPL84) or device within 30 days of first dose with study intervention.
• Use of systemic steroids over 3 consecutive months in the last 6 months prior to screening, or use of systemic steroids in the last month prior to screening. Use of inhaled steroids above 1 mg.
• Use of CF medications, e.g. inhaled antibiotics, dornase alfa (Pulmozyme), hypertonic saline and physiotherapy should be on stable regimen for the period 28 days prior to screening; those participants taking inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at least 90 days prior to first dose with study intervention.
• Any acute infection including acute upper respiratory or lower respiratory infections, pulmonary exacerbation, changes in therapy for pulmonary disease, or any non CF-related illness which results in the initiation of any new therapy within 14 days prior to first dose with study intervention.
• Hemoptysis of greater than 30 mL within 90 days prior to Day 1, or hospitalization for hemoptysis within 6 months of first dose with study intervention.
• Liver disease characterized by clinically significant cirrhosis and/or documented portal hypertension.
• History of any organ transplantation.
• Documented coronavirus disease (COVID-19) infection within 4 weeks prior to dosing.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• SPL84
SPL84 solution for nebulization

Other:
• Placebo
Placebo solution for nebulization

Locations

Country	Name	City	State
United States	University of Alabama at Birmingham	Birmingham	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
SpliSense Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)	Incidence, nature, and severity of AEs and SAEs	Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rate		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rate		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressure		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetry		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperature		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test results		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test results		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test results		Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parameters	using an ECG machine that automatically calculates heart rate and measure PR, QRS, QT, and QTc intervals	Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findings	Complete physical examinations include general appearance, head, ears, eyes, nose, throat, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.	Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests results	Pulmonary function tests will be performed according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) and forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF25-75) will be measured	Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal sputum microbiology results results	Sputum microbiology will be performed with a microbiology based assay; organism growth will be identified.	Day 1 through Day 87
Primary	Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity results	assessment of anti-SPL84 antibodies will be performed both in serum and sputum	Day 1 through Day 87
Secondary	Characterization of pharmacokinetics (PK) of SPL84: maximum serum concentration (Cmax)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of PK of SPL84: Time to Cmax (Tmax)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of PK of SPL84: terminal elimination half-life (t1/2)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of PK of SPL84: Area under the curve to the final sample (AUC0-t)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of PK of SPL84: Area under the curve to infinity (AUC0-8)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of PK of SPL84: Apparent clearance (CL/F)		Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
Secondary	Characterization of excretion of SPL84: concentration of SPL84 in urine		Day 1 through Day 87
Secondary	Preliminary efficacy of SPL84 as assessed by change from baseline in percent predicted FEV1	Pulmonary function tests will be performed according to the ATS/ERS	Day 1 through Day 87
Secondary	Preliminary efficacy of SPL84 as assessed by change from baseline in Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score	The score for is standardized on a 0- to 100-point scale on which higher scores represent a higher quality of life	Day 1 through Day 87
Secondary	Preliminary efficacy of SPL84 as assessed by change from baseline in body weight		Day 1 through Day 87
Secondary	Preliminary efficacy of SPL84 as assessed by change from baseline of antibiotic treatment		Day 1 through Day 87